INTRODUCTION AND OBJECTIVES:
Proteostasis is a complementary process by which cells control the protein biosynthesis, folding, trafficking and degradation. Evidence suggests that proteomic instability, such as protein misfolding and aggregation plays pivotal roles in cancer cell survival and progression. AR-V7 lacking the ligand binding domain confers resistance to enzalutamide and abiraterone in prostate cancer, targeting AR-V7 is an logical strategy to overcome the resistance. However, the mechanisms of AR-V7 proteostasis have not been fully studied so far. The objectives of this project are to investigate the roles of proteostasis in regulating AR-V7 expression and sensitivity to enzalutamide and abiraterone treatment.
METHODS: Expression of HSP70 and STUB1 was determined by qRT-PCR and western blot. Expression of HSP70 and STUB1 was downregulated using specific siRNA. HSP70/STUB1 and AR-V7 interaction was determined by co-immunoprecipitation and dual immunofluorescence. The gene regulating mechanisms underlying the HSP70 inhibition in drug resistant prostate cancer cells was determined by RNA sequencing analyses. The effects of HSP70 inhibition on enzalutamide sensitivity were examined in vitro and in vivo. The correlation between HSP70 and AR-V7 in high Gleason score prostate tumors was determined by qRT-PCR.
RESULTS: In the present study, we analyzed enzalutamide and abiraterone resistant prostate cancer cells and found ubiquitin mediated proteolysis pathway was suppressed, and E3 ubiquitin ligases STUB1 is down regulated in enzalutamide and abiraterone resistant prostate cancer cells. STUB1 binds to AR-V7, degrades AR-V7 expression and suppresses its activity. HSP70, the STUB1 binding protein, also binds to AR-V7 and enhances AR-V7 transcriptional activity. Mechanistically, STUB1 disassociates HSP70 from AR-V7 binding and increases AR-V7 ubiquitination and degradation. Targeting HSP70 by siRNA or small molecular inhibitors (Apoptozole and Ver155008) significantly suppressed prostate cancer growth and improved enzalutamide and abiraterone treatment through AR-V7 inhibition in vitro and in vivo. Additionally, HSP70 expression is upregulated in mCRPC tumors and correlates with AR-V7 levels in high Gleason score and metastatic prostate tumor specimens.
CONCLUSIONS: Enzalutamide and abiraterone treatment induces the imbalance of AR-V7 proteostasis through the ubiquitinproteolysis alteration. HSP70/STUB1 complex controls AR and AR variants proteostasis. Targeting HSP70 could be a valuable strategy to overcome the next generation anti-androgen resistance and improve their therapy. signaling is a distinctive feature of prostate cancer (PCa) and represents a major therapeutic target for treating metastatic prostate cancer (mPCa). Thus, androgen deprivation therapy (ADT) is a first-line treatment for mPCa. Although initially highly effective as a treatment for mPC, ADT is characterized by the frequent emergence of resistance, a disease state termed castration-resistant prostate cancer (CRPC) and is generally incurable after progression to metastatic disease. Therefore, understanding the mechanisms underlying CRPC and subsequent progression to metastatic disease is critical. In our previous study, which was mainly focused on how transcriptional networks change in response to ADT and lead to metastasis, we analyzed matched pre-ADT and post-ADT tissue samples via RNAseq analysis of 40 formalin-fixed paraffin-embedded (FFPE) patient-matched pre-ADT biopsy (Bx) and post-ADT radical prostatectomy (RP) prostate cancer samples. We observed strong upregulation of components of the MAPK pathway including FOS, FOSB, and JUN, as well as downstream targets of MAPK signaling. These data suggest that ADT may induce a compensatory increase in MAPK signaling in response to the decrease in androgen signaling. Thus, we hypothesize that combination therapies targeting AR and the MAPK pathway may synergistically kill prostate cancer cells and prevent recurrence and progression to CRPC.
METHODS: Cell Viability and Cytotoxicity Assays, MTT assays, Transwell Cell Migration and Invasion assays were used to evaluate the viability, cytotoxicity, proliferation, migration and invasion abilities of LNCaP cell after treated with Enzalutamide and MEK inhibitors PD0325901 and GSK1120212, ERK1/2 inhibitor GDC-0994, and the JNK inhibitor AS602801 alone and in combination with enzalutamide in androgen-sensitive LNCaP and MDA-PCa-2b cells. Western blot analysis was conducted to detect the expression of androgenreceptor(AR) and prostate-specific antigen(PSA), p-Erk/Erk, p-JNK/JNK. RESULTS: Cell viability assays indicated that enzalutamide combined with MEK and JNK inhibitors synergistically killed LNCaP, and decreased migration and invasion of LNCaP cell more than any of the drugs alone.
CONCLUSIONS: combination therapy targeting AR and MEK and/or JNK signal pathways may be an effective treatment for recurrent prostate cancer. We are currently investigating the most promising combinations of enzalutamide with JNK inhibitors for anti-tumorigenic effects in vivo using a mouse xenograft model. INTRODUCTION AND OBJECTIVES: Positive surgical margins (PSM) are associated with an increased risk of biochemical recurrence (BCR) in prostate cancer (PCa) patients undergoing radical prostatectomy (RP). Nonetheless, not all patients with PSM ultimately experience clinical recurrence or cancer-specific mortality (CSM) given also the impact of other cause mortality (OCM).
METHODS: Overall, 5388 PCa patients treated with RP between 2000 and 2017 were identified. Patients who did not receive adjuvant therapies and with PSMs (n[913; 17%) were then identified. Of these, 615 (67%) who had available details on total length (mm) and focality (single vs. multiple). Unfavourable PSM was defined as a margin !3 mm or multifocal. CSM was defined as death from PCa.
